Innovotech Inc. (TSX-V: IOT), a pioneer in the field of biofilm product development, has signed an exclusive distribution agreement with LevPharm Ltd of Israel to market and distribute its bioFILM PA- test to hospitals and clinics within Israel.
"We are very excited to enter into this agreement with LevPharm, who recognize the significant impact the bioFILM PA- test can have on improving patient care while reducing the cost burden to health care systems," said Ken Boutilier, President and CEO of Innovotech Inc. "The partnership with LevPharm illustrates their understanding of the importance of technologies for biofilm management, and further demonstrates Israel's leadership in embracing innovative products and solutions to enhance their health care system."
The current market capacity in Israel for acute infection treatment alone is estimated to be over 3,000 bioFILM PA- tests per year.
bioFILM PA- is the first diagnostic test to assist physicians in the selection of the most effective combination antibiotic treatment of patients with biofilm-based Pseudomonas aeruginosa infections.
Pseudomonas aeruginosa is a common bacterium responsible for many hospital acquired infections including ventilator-associated pneumonia and those found in patients with burns and wounds. It is also one of the major causes of lung infections in individuals with Cystic Fibrosis.
Over eighty percent of microbial infections in the body are caused by organisms in a biofilm state. Biofilm infections are known to be up to 4,000 times more resistant to antibiotics than the same organism in a free-floating state, which demonstrates why it is so critical to identify effective treatments early, such as through the bioFILM PA- test.
Sexual minority adults more likely to avoid care on the basis of patient-clinician identity discordance